Abstract
Direct-to-family clinical trials efficiently provide data while reducing the participation burden for children and their families. Although these trials can offer significant advantages over traditional clinical trials, the process of designing and implementing direct-to-family studies is poorly defined, especially in children with rheumatic disease. This paper provides lessons learnt from the design and implementation of a self-controlled, direct-to-family pilot trial aimed to evaluate the effects of a medication management device on adherence to hydroxychloroquine in paediatric SLE. Several design features accommodate a direct-to-family approach. Participants meeting eligibility criteria from across the USA were identified a priori through a disease registry, and all outcome data are collected remotely. The primary outcome (medication adherence) is evaluated using electronic medication event-monitoring, plasma drug levels, patient questionnaires and pill counts. Secondary and exploratory endpoints include (1) lupus disease activity measured by a remote SLE Disease Activity Index examination and the Systemic Lupus Activity Questionnaire; and (2) hydroxychloroquine pharmacokinetics and pharmacodynamics. Recruitment of the initi...Continue Reading
References
Mar 29, 2007·Annals of the Rheumatic Diseases·Graciela S AlarcónUNKNOWN LUMINA Study Group
Oct 13, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Thomas V O HansenYrsa Andersen Hundrup
Nov 13, 2012·Annals of the Rheumatic Diseases·Nathalie Costedoat-ChalumeauUNKNOWN Group PLUS
Feb 22, 2013·Journal of Medical Economics·Cindy GarrisGreg Dennis
Nov 19, 2013·Best Practice & Research. Clinical Rheumatology·Nathalie Costedoat-ChalumeauJean-Charles Piette
Dec 12, 2013·British Journal of Clinical Pharmacology·Pathma D JosephDr Patrina Hy Caldwell
May 6, 2014·Contemporary Clinical Trials·Miguel OrriSteven R Cummings
May 24, 2014·La Presse médicale·Nathalie Costedoat-ChalumeauGaëlle Guettrot-Imbert
Jul 16, 2015·Contemporary Clinical Trials·Carmen RosaErin L Winstanley
Jan 7, 2016·JMIR Research Protocols·Rachel L RandellMichael D Kappelman
Jan 11, 2016·Arthritis Care & Research·Chi Chiu MokPaul J Jannetto
Jun 3, 2016·The Journal of Rheumatology·Young Bin JooSang-Cheol Bae
Dec 9, 2016·Expert Opinion on Drug Safety·C Ponticelli, G Moroni
Jan 14, 2017·Arthritis Care & Research·Pavandeep MehatMary A De Vera
Aug 11, 2018·Contemporary Clinical Trials Communications·Carsten SommerBryan McDowell
Aug 17, 2018·Contemporary Clinical Trials Communications·David B Fogel
Sep 1, 2018·Lupus Science & Medicine·Rebecca E Sadun, Laura E Schanberg
Apr 24, 2019·Clinical Pharmacology and Therapeutics·Sean Khozin, Andrea Coravos
May 30, 2019·PloS One·Julia A O'RourkeChristopher J McDougle
Mar 4, 2020·Dermatology : International Journal for Clinical and Investigative Dermatology·Zarqa AliSimon Francis Thomsen
Mar 19, 2020·JAMA Cardiology·Guillaume Marquis-GravelW Schuyler Jones
Jun 17, 2020·Pediatric Research·Debra L WeinerUNKNOWN Pediatric Policy Council
Nov 13, 2020·Pediatric Research·Stephen J BalevicChristoph P Hornik